Nicholas Mai , MD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Breast cancers and conditions
- Estrogen receptor-positive breast cancer (ER+)
- HER2-positive breast cancer
My Specialties
- Early-phase clinical trials
- Targeted therapy
- Immunotherapy
Get to Know Me
I’m a medical oncologist who has special training in the treatment of breast cancer. I am also an early drug development specialist, which is a scientist who tests new drugs to treat cancer. I see patients at Memorial Sloan Kettering Monmouth in New Jersey.
Breast cancer is the most common cancer among women, and your diagnosis is unique to you. I work to understand the specific type of breast cancer you have been diagnosed with. I also take the time to make sure you feel informed and confident about your care. As an expert in cancer genomics, one of the many tools I use is genetic testing. This helps guide us toward the best treatment option that meets your needs.
An important lesson I have learned from my mentors through the years is that excellence in medicine is not measured by following a set path. It is measured by expertly navigating the complexity of each person’s case. This principle guides my practice every day. Whether your case follows an expected path or presents special challenges, you can feel assured that I bring both the knowledge and the calm needed to deliver the best care possible.
I am one of the main clinical organizers of MSK’s Molecular Tumor Board, which is a forum of experts across different teams. This includes medical oncologists, surgical oncologists, and radiation oncologists as well as pathologists and radiologists who meet to talk about complex cases twice a month. Through this service, we use the latest data to help patients and providers find the best treatment option or clinical trial.
In addition to patient care, I lead clinical trials through MSK’s early drug development service. Through these groundbreaking studies, we give people access to the most promising new therapies before they are widely available. This helps create possible paths forward when standard treatments have reached their limits.
Ultimately, I’ll guide you through your journey with clarity and compassion. With the support of the entire MSK team, we will be with you every step of the way, making sure you get the expert, personal care you deserve.
I'm a breast medical oncologist, which is a cancer doctor who specializes in breast cancer.
I'm an early drug development specialist, which is a scientist who tests new drugs to treat cancer. I have special training in research studies, also known as clinical trials.
- Assistant Attending Physician
Conditions I Treat
- Breast cancers and conditions
- Estrogen receptor-positive breast cancer (ER+)
- HER2-positive breast cancer
- Triple-negative breast cancer (TNBC)
- Metastatic (secondary) breast cancer
My Specialties
- Early-phase clinical trials
- Targeted therapy
- Immunotherapy
- Antibody therapy
Education
- MD, Johns Hopkins University School of Medicine
- BA, Princeton University
Residencies
- Internal Medicine, Johns Hopkins Hospital
Fellowships
- Medical Oncology, Memorial Sloan Kettering Cancer Center
Board Certifications
- Medical Oncology
- Internal Medicine
Awards and Honors
- Brian Piccolo Endowed Cancer Research Fellowship Award, Brian Piccolo Cancer Research Fund (2023-2025)
- Theresa Foss Fellowship in Breast Cancer Medicine, Theresa Foss Foundation (2024)
- John Mendelsohn Housestaff Teaching Award 2022-2023, Memorial Sloan Kettering Cancer Center (2023)
- Memorial Sloan Kettering Clinical Scholars T32 Award, Memorial Sloan Kettering Cancer Center (2023-2025)
- J. Mario Molina Physician Scientist Scholar's Award, Johns Hopkins Hospital (2021)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, EPO, HMO
In Network Coverage Type
State Government
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
State Government
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
TBD
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO/EPO
In Network Coverage Type
PPO, EPO
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Mai
- A Phase 1 Study of BMS-986500 in People With Advanced Solid Tumors
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Nicholas Mai et al. Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan. JCO 42, 1085-1085(2024).
Nicholas Mai et al. Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response. JCO 42, 1078-1078(2024).
Mai N, Dos Anjos CH, Razavi P, Safonov A, Patil S, Chen Y, Drago JZ, Modi S, Bromberg JF, Dang CT, Liu D, Norton L, Robson M, Chandarlapaty S, Jhaveri K. Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer. NPJ Breast Cancer. 2024 Oct 18;10(1):92. doi: 10.1038/s41523-024-00699-3. PMID: 39424631; PMCID: PMC11489574.
Mai N, Myers S, Shen S, Downs-Canner S, Robson M, Norton L, Chen Y, Traina T, Abuhadra N. Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer. NPJ Breast Cancer. 2024 Jun 4;10(1):39. doi: 10.1038/s41523-024-00643-5. PMID: 38834621; PMCID: PMC11150442.
Mai N, Chen JF, Rana S, Robson M, Chandarlapaty S, Rosen EY. Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer. NPJ Precis Oncol. 2024 Jul 28;8(1):162. doi: 10.1038/s41698-024-00631-9. PMID: 39069534; PMCID: PMC11284213.
Visit PubMed for a full listing of Dr. Mai’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Nicholas Mai discloses the following relationships and financial interests:
-
Integrity Continuing Education, Inc.
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.